ALLMedicine™ Atypical Hemolytic Uremic Syndrome Center
Research & Reviews 397 results
Hypertension (Dallas, Tex. : 1979); Burwick RM, Moyle K et. al.
Jul 19th, 2021 - Pregnancy-associated atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic microangiopathy which may be mistaken for hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. We sought to identify laboratory ...
https://doi.org/10.1007/s00467-021-05193-7 10.1007/s00467-009-1137-6 10.1681/ASN.2019040331 10.1097/MOH.0b013e32833cae86 10.1186/1750-1172-6-60 10.1097/MJT.0b013e31829b59dc 10.1055/s-2001-15247 10.1067/mpd.2003.79 10.1038/ng.2590 10.1007/s00467-015-3076-8 10.1007/s00467-014-2817-4 10.1056/NEJMc0809959 10.1542/peds.2011-1685 10.1056/NEJMoa1208981 10.1111/j.1399-3089.2006.00279.x 10.1007/s00467-012-2279-5 10.1097/TP.0000000000001325 10.1182/blood-2018-09-876805 10.1007/s00467-014-2868-6 10.1007/s40265-019-01068-2
Pediatric Nephrology (Berlin, Germany); Stojanovic J, Adamusiak A et. al.
Jul 17th, 2021 - A 3-year-old girl with clinical features of atypical HUS (complement Factor I mutation inherited from an asymptomatic mother and Factor H autoantibodies) was treated with plasma exchange, progressed to kidney failure (KF) aged 4 years, and receive...
Blood Martin Merinero H, Zhang Y et. al.
Jun 30th, 2021 - Atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic microangiopathy that can progress, when untreated, to end-stage renal disease. Most frequently, aHUS is caused by complement dysregulation due to pathogenic variants in gen...
https://doi.org/10.1007/s40620-021-01057-3 10.1016/j.jinf.2020.03.037 10.1016/j.kint.2020.05.013 10.1182/blood.2020008248 10.1161/CIRCULATIONAHA.120.047419 10.1056/NEJMoa1208981 10.1016/j.phrs.2020.105250 10.1016/j.eclinm.2020.100590 10.1093/ckj/sfaa166 10.1016/j.kint.2020.10.030
Journal of Nephrology; Cognard N, Gautier-Vargas G et. al.
May 17th, 2021 - COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report.|2021|Cognard N,Gautier-Vargas G,Perrin P,Benotmane I,Caillard S,|
Blood Reviews; Delvasto-Nuñez L, Jongerius I et. al.
May 14th, 2021 - Thromboembolic events represent the most common complication of hemolytic anemias characterized by complement-mediated hemolysis such as paroxysmal nocturnal hemoglobinuria and autoimmune hemolytic anemia. Similarly, atypical hemolytic uremic synd...
Guidelines 3 results
Clinical and Experimental Nephrology; Kato H, Nangaku M et. al.
Jul 16th, 2016 - Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely ...
Pediatric Nephrology (Berlin, Germany); Loirat C, Fakhouri F et. al.
Apr 10th, 2015 - Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulation. This advance facilitated the development of novel, rational treatment options targeting terminal complement activation, e.g....
Pediatric Nephrology (Berlin, Germany); Ariceta G, Besbas N et. al.
Sep 18th, 2008 - This guideline for the investigation and initial treatment of atypical hemolytic uremic syndrome (HUS) is intended to offer an approach based on opinion, as evidence is lacking. It builds on the current ability to identify the etiology of specific...
Drugs 3 results see all →
Clinicaltrials.gov 6 results
Oct 17th, 2018 - This is a Phase 3, multicenter study of OMS721 in adults and adolescents with atypical hemolytic uremic syndrome (aHUS). The uncontrolled, open-label study will evaluate the effect of OMS721 in subjects with plasma therapy-resistant aHUS and plasm...
Sep 2nd, 2018 - This clinical trial is a prospective single arm multi-institution study in children and young adults undergoing allogeneic or autologous hematopoietic stem cell transplantation who will receive early therapy with eculizumab to prevent TMA-associat...
Nov 13th, 2017 - Inherited defects that determine uncontrolled activation of the alternative complement pathway have been well documented in atypical Hemolytic Uremic Syndrome (aHUS) patients. Research in recent years has identified more than 120 different mutatio...
Jul 22nd, 2015 - The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS).
Jan 17th, 2013 - The objective of this retrospective trial is to assess safety and efficacy of eculizumab in aHUS patients treated outside of an Alexion-sponsored controlled clinical trial.
News 26 results
Apr 20th, 2020 - (Reuters) - Alexion Pharmaceuticals Inc said on Monday it would start a late-stage study of its rare blood-disorder drug, Ultomiris, in COVID-19 patients hospitalized with severe pneumonia or acute respiratory distress syndrome. The study is expec...
Oct 20th, 2019 - The US Food and Drug Administration (FDA) has approved ravulizumab (Ultomiris, Alexion Pharmaceuticals) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and children age 1 month or older with atypical hemolytic uremic synd...
May 3rd, 2019 - PHILADELPHIA — Intravenous eculizumab (Soliris, Alexion Pharmaceuticals) significantly decreased risk for relapse in patients with neuromyelitis optical spectrum disorder (NMOSD) over placebo, in a new multicountry phase 3 study. Findings from PRE...
Jan 29th, 2019 - Note that some links may require subscriptions. Researchers linked handgun ownership to an increase in child deaths. (CNN Health, Pediatrics) The FDA boasted that 2018 was a "record year for device innovation" with 106 novel products approved, up ...
Oct 26th, 2018 - The Food and Drug Administration has granted OMS721 orphan designation for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (HSCT-TMA). OMS721 is a monoclonal antibody targeting MASP-2, the effector enzyme.